One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

The firms will evaluate two adjuvant treatment options, Datroway with rilvegostomig or rilvegostomig monotherapy, against standard-of-care treatment.

DelveInsight’s, “Squamous Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 75+ companies and 80+ ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

Innate Pharma (NASDAQ:IPHA – Get Free Report) and Agenus (NASDAQ:AGEN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based ...

Atezolizumab (Tecentriq) plus chemotherapy after surgery did not improve survival in high-risk triple-negative breast cancer, ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

Virtual reality has been a standout technology in the medical industry since the turn of the decade. From its use as a ...

The drug is already approved to treat non-metastatic ... and the ANZUP trial looking at adjuvant (post-surgery) use of Nubeqa in localised prostate cancer with a high risk of recurrence.